| ID | 1105 |
| Name of the vaccine | mORC-Vax |
| Microbe | Bacteria |
| Disease name | Cholera |
| Name of bacteria | Vibrio cholerae |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | 2 years and older |
| Description of the vaccine | Bivalent, killed whole-cell (O1 and O139 serogroups). Licensed only in Vietnam. |
| Name of the manufacturer | Vabiotech, Hanoi |
| Name of the manufacturing country | Vietnam |
| Year of manufacture | 2009 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative bacteria. |
| Efficacy | Seroconversion rates of vibriocidal antibodies of 91% among adults in Vietnam, 53% among adults in Kolkata and 80% among children aged greater than 1 year. |
| Vaccine formulation | NA |
| Dosage | Two doses, gap of 14 days. |
| Mechanism of action | NA |
| Route of administration | Oral |
| Indications | NA |
| Export | Not for international use |
| Approval | Not WHO prequalified. |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | 31879125 |
| Clinical trial number | NA |
| Reference | https://www.who.int/bulletin/volumes/92/12/14-139949.pdf?ua=1 |
| Other name | NA |
| Additional Links | NA
|